To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Double-Boosted Saquinavir/Lopinavir Combination Safe and Effective for Treatment-Resistant Children With AIDS: Presented at CROI URL: http://www.pslgroup.com/dg/21CA3E.htm Doctor's Guide February 7, 2008
By Maria Bishop BOSTON, MA -- February 7, 2008 -- Double-boosted saquinavir/lopinavir (SQV/LPV/r) demonstrated a significant increase in CD4 cell counts and a decline in viral loads at 96 weeks in children with AIDS who were resistant to non-nucleoside- and nucleoside reverse transcriptase inhibitors (NNRTIs/NRTIs), according to research presented here at the 15th Conference on Retroviruses and Opportunistic Infections (CROI). In this prospective study, 50 NNRTI/ NRTI pretreated Thai children from Bangkok (n = 20) and Khon Kaen (n = 30) were treated with twice-daily SQV-mesylate capsules and LPV/r. According to lead author Torsak Bunupuradah, MD, Pediatrician, The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, the children from the Khon Kaen site had a higher mean viral load at baseline than did the children from the Bangkok site (4.9log10 vs 4.7log10, respectively, P =.037). Median CD4 percentage and CD4-count increase were 14% and 558 cells/mm3 at 96 weeks (both P <.001), and the median viral load reduction was -2.8log10 (P <.001). There were no cases of disease progression during the study period. Viral load failure was seen in 1 of the 20 children from the Bangkok site and in 5 of the 30 children from Khon Kaen; 3 of these 6 failures occurred in children with poor adherence to therapy. Three children died from a bacterial infection, while 2 stopped antiretroviral therapy -- 1 due to intolerance and the other due to noncompliance. Therapy-related adverse events were seen in 10 children (20%); of these, 61% were grade 1 to 2 adverse events and 39% were grade 3 to 4. The most common adverse events were diarrhea, vomiting, and elevated triglycerides. Baseline lipoatrophy was reported in the arm (12%) and face (8%); 2% reported abdominal lipohypertrophy at baseline. At 96 weeks, approximately half of the subjects had no change in body shape, while 33%, 43%, and 39% reported fatter arms, face, and abdomen, respectively. A significant increase of 14 points was observed in the median high-density lipoprotein level (P =.004). [Presentation title: Efficacy and Safety of Double-Boosted SQV/LPV/r Combination at 96 Weeks in Thai Children Who Have Failed NRTI/NNRTI-Based Regimens. Abstract 586] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.